anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an acicular nano hydroxyapatite material of good absorption capability. The absorption content of lysozgme with different concentration (0.2mg/ml-1.0mg/ml) of the material is 2.14 percent to 19.06 percent, with the highest absorption rate of 95 percent above. The slow-release property of the material is controllable with the slow-release time being controlled between 60min and 960min, while the slow-release rate can be controlled between 60 percent and 95 percent. The release speed of the material can be adjusted by changing the type and pH value of desorption solution. The weak crystallizing hydroxyapatite takes a calcic compound and phosphorus compound solution as a raw material which goes through processes of dropping, reaction, ethanol decentralization, stirring or aging at room temperature, and then the material is prepared. The particle diameter of the hydroxyapatite prepared is at a nano level and distributed evenly and the particles thereof are characterized by low crystallinity, large specific surface area, high surface activity and the like. The adsorption of the lysozgme is completed by selecting a phosphate buffer solution with pH being equal to 7.3, based on the electrostatic interaction, and is characterized by short adsorption time and large adsorption quantity. The acicular nano hydroxyapatite material has the advantages of easily available raw materials, low cost and simple operation and the material obtained has good adsorbability and controllable slow-release property, thus the material can be used as a slow-release carrier of basic proteins such as lysozgme, etc.
Coronary heart disease (CHD) is a public health care challenge, which lead to 3.5 millions of people died in China every year. There are three types of treatment for CHD, medication, percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG). However, some end-stage CHD patients with severe cardiac ischemia lost the chance to get those treatment. Their quality of life is influenced by recurrent angina. Cardiac shock wave therapy (CSWT) is a new developed therapy for these patients, which is used in tens of countries all over the world. German and Japan are the countries earliest used CSWT. Safety, invasiveness, effectiveness is its advantage. Ischemia condition can be improved after CSWT by objective examination. New small vessels generation on ischemia area was found on mice and pig model. There are only three cities in China run the program of CSWT, that are Kunming, Beijing and Shanghai. Beijing hospital has the only CSWT machine in Beijing. The investigators designed a randomized double-blind study to evaluate the effectiveness and safety of CSWT.
Electrical storm (ES) is characterized by three or more discrete sustained ventricular tachyarrhythmia episodes occurring within a limited time frame (generally ≤ 24 h) or an incessant ventricular tachyarrhythmia lasting > 12 h. In patients with an implantable cardioverterdefibrillator (ICD), ES is defined as three or more appropriate device therapies, separated from each other by at least 5 min, which occur within a 24-h period. ES may constitute a medical emergency, depending on the number arrhythmic episodes, their duration, the type, and the cycle length of the ventricular arrhythmias, as well as the underlying ventricular function. This narrative review was facilitated by a search of MEDLINE to identify peer-reviewed clinical trials, randomized controlled trials, meta-analyses, and other clinically relevant studies. The search was limited to English-language reports published between 1999 and 2023. ES was searched using the terms mechanisms, genetics, channelopathies, management, pharmacological therapy, sedation, neuraxial modulation, cardiac sympathetic denervation, ICDs, and structural heart disease. Google and Google scholar as well as bibliographies of identified articles were reviewed for additional references. This manuscript examines the current strategies available to treat ES and compares pharmacological and invasive treatment strategies to diminish ES recurrence, morbidity, and mortality.
In this pilotstudy there are two human volunteers. The study comprises two phases. The first phase: The volunteers are applying a commercially available sunscreen lotion containing titanium dioxide nano particles 6 times a day for one week in an area of the back that is 30x20 cm. Before the first application a 2mm punch biopsy is to be taken and examined by scanning electron microscopy. After applying sunscreen lotion for a week, a new biopsy will be taken in order to see how far down in the skin the particles have penetrated. In the second phase: An artificial sunburn will be induced in the same area of the back. They will thereafter apply the sunscreen lotion 6 times a day like in the first phase. After two days (estimated time of maximum skin irritation) a biopsy will be taken in order to see if the nanoparticles have penetrated down in the layers of the skin, and the investigators will also take a biopsy after a full week of applying the sunscreen lotion. The investigators will also examine the urine, before and after the use of sunscreen, to see if the investigators can find the particles there.
We investigated the association between dietary intake and metabolic risk factors in children and adolescents within a semi-rural Malaysian community. Using an interviewer-led questionnaire, we surveyed 623 participants aged 7-18 from the South East Asia Community Observatory (SEACO). Anthropometric and blood pressure data were collected from all participants, while a subset (n = 162) provided blood samples for biomarker analysis, including fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Metabolic syndrome was determined using the International Diabetes Federation's Definition of Metabolic Syndrome in Children and Adolescents. Most participants were Malay (66.8%), with a median household income of MYR1,500 and a balanced sex distribution. Cereals, processed foods, beverages, fruits, and vegetables were commonly consumed. Obesity and abdominal obesity were prevalent, affecting more than a third of participants. Adherence to dietary recommendations was generally poor (ranging from 19.9 to 58.1%) and varied across age, sex, and ethnicity. Notably, some food groups displayed unexpected associations with health markers; for instance, fruit consumption was linked to abdominal obesity in children (abdominal obesity vs. normal: 2.4 servings/day vs. 1.6 servings/day). These findings emphasise the necessity of longitudinal studies to explore the complex relationship between diet and long-term health outcomes, including cardiometabolic diseases, while acknowledging the unique challenges posed by the COVID-19 pandemic on data collection and analysis.
An insulin analog comprises a B-chain polypeptide incorporating a chlorinated phenylalanine. The chlorinated phenylalanine may be located at position B24. The chlorinated phenylalanine may be para-monochloro-phenylalanine. The analog may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analog. The chlorinated insulin analogs retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to a patient. Chlorine substitution-based stabilization of insulin may reduce fibrillation and thereby enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration.
NEMOS taVNS electrodes will be placed in the left concha cymba of participants (CerboMed GmbH, Erlangen, Germany). When appropriate, these electrodes will be plugged into a digitimer. Whilst pulse width, frequency, stimulation burst and total duration will be respectively standardized to 200microseconds, 20Hz, 30seconds on and 30seconds off and 20minutes, the stimulation will be person specific. To acquire this intensity, participants will perform a thresholding protocol. Based on an elegant stair-case algorithm, the perception and pain (described as a 7/10 pain level, where 10 is the most amount of pain imaginable) thresholds will be obtained. Stimulation intensity will then be defined as 2/3 the range between these thresholds. For example, if the perception and pain thresholds are respectively at 2mA and 8mA, the stimulation intensity would be 6mA.
Ropinirole used to treat Parkinson's disease highly targets the dopaminergic receptor D3 over the D2 receptor but although both are expressed in the kidneys the ropinirole potential to treat kidney injury provoked by ischemia/reperfusion (I/R) is undraped. We investigated whether ropinirole can alleviate renal I/R by studying its anti-inflammatory, antioxidant, and anti-pyroptotic effects targeting its aptitude to inhibit the High-mobility group box 1/Toll-like receptor 4/Nuclear factor-kappa B (HMGB1/TLR4/NF-κB) cue and the canonical/non-canonical NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome trajectories. Herein, bilateral I/R surgery was induced in animals to be either untreated or treated with ropinirole for three days after the insult. Ropinirole successfully improved the histopathological picture and renal function which was confirmed by reducing cystatin C and the standard parameters creatinine and blood urea nitrogen (BUN). Ropinirole achieved this through its anti-inflammatory capacity mediated by reducing the HMGB1/TLR4 axis and inactivating NF-κB, which are upstream regulators of the NLRP3 pathway. As a result, the injurious inflammasome markers (NLRP3, apoptosis-associated speck-like protein (ASC), active caspase-1) and their target cytokines interleukin-1 beta (IL-1β) and IL-18 were decreased. Ropinirole also reduced the pyroptotic cell death markers caspase-11 and gasdermin-D. Furthermore, ropinirole by replenishing antioxidants and decreasing malondialdehyde helped to reduce oxidative stress in the kidneys. The docking findings confirmed that ropinirole highly binds to the dopaminergic D3 receptor more than to the D2 receptor. In conclusion, ropinirole has the potential to be a reno-therapeutic treatment against I/R insult by abating the inflammatory NLRP3 inflammasome signal, pyroptosis, and oxidative stress.
PURPOSE:To obtain mammalian T cell activator, especially interleukin 2-derivative, useful as an antitumor agent, radiation damage preventing agent, remedy for immunodeficiency and anti-inflammatory drug without causing heat generation, containing histone H2B derived from mammal. CONSTITUTION:A T cell activator having extremely low heat generation, especially interleukin-2-(IL-2) inducer, containing histone H2B derived from a mammal such as human, bovine, mouse, etc., as an active ingredient. IL-2 multiplies antigen specific T cell against tumor antigen. Since the T cell suppresses growth of tumor, IL-2 is effective for treating tumors. IL-2 induces production of gamma-interferon and activates a natural killer cell. Further IL-2 is useful for treating diseases related to function disorder of immune system, such as immunodeficiency including AIDS, multiple selerosis and rheumatoid arthritis.
FIELD: medicine, dermatology. SUBSTANCE: method involves the use of broad spectrum antibiotic to which microorganism associated with disease show sensitivity. Preparation is administrated in region of nodular erythema members. Gentamycin is used at total dose 80-160 mg in 10 ml 0.25% novocaine. Injections are repeated 2 times per a week up to complete disappearance of disease symptoms, 2-4 seances per a course. Rate of effect onset was above that obtained with nonsteroid antiinflammatory preparations and corticosteroids. Method was effective in all patients. EFFECT: enhanced effectiveness of treatment. 1 tbl
This group will undergo physical therapy exercises per the standard of care, with the addition of Blood Flow Restriction (BFR) utilizing a wide pressure cuff. BFR exercises will be initiated two weeks post-op, and continued for 16 weeks.
The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
PURPOSE: A composition for treating tumor containing N-terminal-deleted WT1(Wilm's tumor protein) and specific T-cells is provided to use in immunotherapy for tumor. CONSTITUTION: A recombinant adenovirus contains a gene encoding 1-147 amino acids-deleted WT1. The mutated WT1-specific T cell is obtained by stimulating T cell with dentritic cells which is transformed by the recombinant adenovirus. The T cell is CD4+ and CD8+ T cell. A composition for treating tumor contains the mutated WT1-specific T cell. A method for testing the efficiency of the mutated WT1-specific cell comprises: a step of performing immune response to an epitope of 1-147 amino acid of WT1 in the T cell in which the mutate T cells are injected or a protein containing the epitope; and a step of analyzing the immune response. The analysis is performed by FACS(fluorescence-activated cell sorting) or ELISPOT(enzyme-linked immuno spot).
Coronary artery bypass surgery can result in endothelial dysfunction due to ischemia/reperfusion (IR) injury. Previous studies have demonstrated that DuraGraft helps maintain endothelial integrity of saphenous vein grafts during ischemic conditions. In this study, we investigated the potential of DuraGraft to mitigate endothelial dysfunction in arterial grafts after IR injury using an aortic transplantation model. Lewis rats (n = 7-9/group) were divided in three groups. Aortic arches from the control group were prepared and rings were immediately placed in organ baths, while the aortic arches of IR and IR + DuraGraft rats were preserved in saline or DuraGraft, respectively, for 1 h before being transplanted heterotopically. After 1 h after reperfusion, the grafts were explanted, rings were prepared, and mounted in organ baths. Our results demonstrated that the maximum endothelium-dependent vasorelaxation to acetylcholine was significantly impaired in the IR group compared to the control group, but DuraGraft improved it (control: 89 ± 2%; IR: 24 ± 1%; IR + DuraGraft: 48 ± 1%, p < 0.05). Immunohistochemical analysis revealed decreased intercellular adhesion molecule-1, 4-hydroxy-2-nonenal, caspase-3 and caspase-8 expression, while endothelial cell adhesion molecule-1 immunoreactivity was increased in the IR + DuraGraft grafts compared to the IR-group. DuraGraft mitigates endothelial dysfunction following IR injury in a rat bypass model. Its protective effect may be attributed, at least in part, to its ability to reduce the inflammatory response, oxidative stress, and apoptosis.
Participants will attend 12 weekly 30-45-minute individual counseling sessions and receive tailored lesson materials focused on behavioral strategies for adopting and maintaining healthy eating and physical activity (PA) behaviors. Participants will self-monitor their body weight, eating, and PA behaviors in a weekly journal. Dietary recommendations will follow nutritional guidelines for the treatment of NAFLD. To facilitate the adoption of the dietary recommendation, participants will be provided culturally-tailored meal plans and grocery lists that allow them to make small, practical dietary changes of \~100 calories. Participants will be prescribed weekly exercise goals with the duration increasing from 15-45 minutes, 5 days/week, over the 12-month program. After the completion of 12 weekly individual counseling sessions, participants will complete a 12-week follow-up including bi-weekly phone calls, followed by a 6-month follow-up period in which no intervention contact is made.
EnREP begins with the same activities as foundational REP. Sites that do not meet EBP-specific a priori benchmarks reflecting adoption within 6 months will continue with foundational REP and will receive higher intensity support for a period of 6 months (enREP). Additionally, sites randomized to enREP that met adoption benchmarks but did do not meet the sustainment benchmark, will also receive intensified implementation support for the remainder of the study period (3 months). The higher intensity support will include one-on-one calls approximately every 3 to 4 weeks between site implementation teams and a trained practice facilitator (from Function QUERI team). The facilitator will coach individual sites using techniques, processes, and activities to help teams make decisions and identify and solve problems. Facilitators? actions will depend on each site?s needs and clinical context.
OBJECTIVE: The present study explored the hypothesis that anhedonia reflects an emotional memory impairment for pleasant stimuli, rather than diminished hedonic capacity in individuals with schizophrenia (SZ).
METHOD: Participants included 30 SZ and 30 healthy controls (HCs) subjects who completed an eye-tracking emotion-induced memory trade-off task where contextually relevant pleasant, unpleasant, or neutral items were inserted into the foreground of neutral background scenes. Passive viewing and poststimulus elaboration blocks were administered to assess differential encoding mechanisms, and immediate and 1-week recognition testing phases were completed to assess the effects of delay interval. Participants also made self-reports of positive emotion, negative emotion, and arousal in response to the stimuli.
RESULTS: Results indicated that SZ experienced stimuli similarly to HC. Both groups demonstrated the typical emotion-induced memory trade-off during the passive viewing and poststimulus elaboration encoding blocks, as indicated by more hits for emotional than neutral items and fewer hits for backgrounds paired with emotional than neutral items. Eye-tracking data also indicated that both groups were more likely to fixate earlier and have longer dwell time on emotional than neutral items. At the 1-week delay, the emotion-induced memory trade-off was eliminated in both groups, and SZ showed fewer overall hits across valence conditions. Greater severity of anhedonia was specifically associated with impaired recognition for pleasant stimuli at the immediate recognition phase.
CONCLUSIONS: Findings suggest that anhedonia in SZ is associated with emotional memory impairment, particularly a deficit in encoding positive stimuli. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
An oxiracetam tablet is provided. The oxiracetam tablet comprises following raw and accessory materials by weight: 1 part of oxiracetam, 0.1-0.6 part of a filler, 0.3-0.5 part of a disintegrating agent, 0.8-1.2 parts of an adhesive and 0.03-0.08 part of a lubricant. The prepared oxiracetam tablet is bright and clean in surface, largely shortened in disintegrating time, fast-acting, high in bioavailability, accurate in dosage, and stable and reliable in quality. The shelf life of the oxiracetam tablet can be 24 months. The oxiracetam tablet is simple in process, and suitable for mechanical production. The yield is high, and 2-3 hundred thousand tablets can be produced in each hour. The oxiracetam tablet is convenient to take, carry, transport and store.
This group consists of patients starting from 2012 to 2013 and includes 87 patients with typical Parkinson's Disease (PD), 15 patients with Progressive Supranuclear Paralysis (PSP), 15 patients with Multiple System Atrophy (MSA), and 15 patients with Cortico-Basal Degeneration (CBD). In differential diagnosis in the first year of the study, diffusion MRI will be used for a retrospective study.
The present invention provides a topical cream composition for the treatment of acne vulgaris and the method of manufacturing thereof. The topical dermatologic acne treatment cream functions through a two-stage process: the clearing the acne currently present on the skin; and reducing the potential reoccurrence of additional acne. The clearing of the presenting acne is accomplished through the use of an acne bactericidal. The reducing the potential reoccurrence of additional acne is accomplished through a skin revitalizing compound that returns the skin to its natural homeostasis thereby encouraging the regrowth of natural, non-acne vulgaris causing, bacterial flora and the microbiome of the skin. The present invention also provides for a method of manufacture the Topical Dermatologic Acne Treatment Cream through two-stage process wherein the bactericidal is added to the skin revitalizing compound. The skin revitalizing compound can be used as a secondary element to various skin conditions or on its own to maintain the general health and skin condition.
PURPOSE: Provided is a method of manufacturing an extract from Platycodon grandiflorum A. DC. which high concentration of crude saponin. The Platycodon grandiflorum A. DC. has excellent pharmacological effect on respiratory diseases. CONSTITUTION: A method of manufacturing an extract from Platycodon grandiflorum A. DC. is characterized by heating Platycodon grandiflorum A. DC. in a heat drier manufactured by ceramics at 110-130 deg.C with spraying nitrogen gas, followed by high frequency treatment, and filtration with a sterilizing filter.
Subjects will undergo imaging assessments during one study day on an outpatient basis. Approximately 10 of these COPD patients will repeat this study day 7-10 days after completion of the first study day to assess the reproducibility of the technique.
Cohort 3 in Part A, participants received romiplostim 1000 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
Circular RNAs (circRNAs) are a new group of endogenous RNAs recently found to be involved in the development of various diseases, including their confirmed involvement in the progression of several types of cancers. Unluckily, the abnormal expression and functions of circRNAs in breast cancer shall be further investigated. This work aims to elucidate the action and molecular mechanism of circHSDL2 in the malignant progression of breast cancer. Differential expression profiles of circRNAs in breast cancer tissues relative to normal breast tissues and in the exosomes of breast cancer patients compared to healthy women were analyzed from databases to identify potentially functional circRNAs. CircHSDL2 was selected for further investigation. Cell proliferation, migration and invasion assays were done to assess the effect of circHSDL2 overexpression on breast cancer cells. Bioinformatics test and dual-luciferase reporter experiments were done to explore the interaction between circHSDL2 and miRNA. Downstream target genes were further investigated through proteomics analysis and Western blotting. The influence of circHSDL2 on breast cancer in vivo was evaluated through xenograft experiments in nude mice. Functional analysis demonstrated circHSDL2 overexpression promoted the division, movement, and invasion of breast cancer cells both in vivo and in vitro. Mechanistically, circHSDL2 acted as a sponge for miR-7978 to affect ZNF704 expression and thereby regulate the Hippo pathway in breast cancer cells. In conclusion, circHSDL2 regulates the Hippo pathway through the miR-7978/ZNF704 axis to facilitate the malignancy of breast cancer. This may be a potential biomarker and treatment target.
In Arm A, patients with NSCLC will receive chemotherapy plus atezolizumab at a flat dose of 1200 mg intravenously (IV) every 3 weeks. Standard of care chemotherapy is defined as a platinum-doublet therapy (or triplet if bevacizumab is used) of the Investigator's choice.